Signaloid Announces Preview of New ASIC Targeted at Physical AI and Robotics Applications
2.6.2026 06:00:00 CEST | Business Wire | Press Release
Signaloid (https://signaloid.com), a computing platform company providing hardware and binary-translation-based acceleration of AI, robotics, aerospace, and quantitative finance workloads, today announced the tapeout and preliminary specifications documents for its C0-ASIC. Delivery of engineering samples to the first customer is due in Q3 2026 and additional FPGA-based systems implementing the ASIC’s design are under discussion for deployment in the UK and Switzerland later in 2026.
The C0-ASIC was targeted specifically at energy-efficient physical AI workloads. The UK Advanced Research and Invention Agency (ARIA) will take delivery of systems based on the ASIC for use in next-generation AI workloads such as second order methods.
“The Scaling Compute program at ARIA commissioned several innovative technology prototypes pursuing unconventional ideas to design new AI accelerators,” says ARIA Program Director Suraj Bramhavar. “We commissioned Signaloid’s C0-ASIC for evaluation in randomized numerical linear algebra and probabilistic computing workloads. We believe randomized linear algebra represents a fundamentally new and powerful technique underpinning many applications in computer science including AI, and exploiting these principles in hardware could provide an entirely new vector for improved performance. We are excited to invest behind this theme, in partnership with Signaloid, to explore its full potential.”
A Different Kind of AI Compute Accelerator
The C0-ASIC implements Signaloid’s distribution-extended compute hardware (UxHw®) technology.
Unlike conventional CPUs and GPUs, which use impressive amounts of sheer compute force across thousands of compute cores, to solve problems that require iterative randomized variations, Signaloid’s UxHw builds on new mathematical techniques to restructure computations, dynamically, to achieve the same results while often using 1000-fold (or more) less energy.
The UxHw technology and its implementation is covered by a growing portfolio of over 90 intellectual property filings in the US, China, Taiwan, Japan, and the EU.
An International Partnership
The design and implementation were the result of a collaboration between Signaloid and world-leading design partners IC-Link by imec and US-based Cadence Design Systems.
“Leading AI hardware innovators trust IC link as a key partner to bring their most advanced ASIC concepts through design and into production with our foundry partner TSMC,” says Ozgur Gursoy, Director Portfolio & Strategy for IC-Link’s ASIC services. “We are proud to have partnered with Signaloid in bringing the C0 Dreadnought ASIC from concept through the design cycle, enabling a new class of compute efficiency for distribution-enhanced computing applications.”
Speaking of the partnership, John Heighton, sales group director, EMEA North and Central at Cadence, said, “Cadence sets the industry standard for enabling leading companies to tape out cutting-edge AI silicon, including Signaloid’s C0-Dreadnought, now in production at TSMC. We support startups advancing next-generation computing by delivering our high-performance Artisan SRAM memories for Signaloid’s ASIC.”
Availability
Engineering samples of bumped dies of the C0-ASIC will be available in Q3 2026. A 2-page preliminary design brief of the C0-ASIC is available immediately, for qualifying customers. Customers interested in robotics and industrial automation use cases will also be able to see the UxHw technology in action at the Bosch Connected World flagship event in Berlin, from 10th-11th June 2026.
About Signaloid
Signaloid was founded by Prof. Phillip Stanley-Marbell, former Professor of Physical Computation at the University of Cambridge and a researcher whose previous roles include Bell Labs, IBM, Apple, and MIT. Signaloid provides a computing platform that benefits computationally-challenging workloads, many of which can be reformulated in terms of algorithms that process probability distributions. Its technology is already used by more than 3,000 users worldwide and is available as cloud, on-premises and low-power edge hardware. www.signaloid.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260530391395/en/
Contacts
Press contact: press@signaloid.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom